Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease

Blood

Volumn 103, Issue 4, 2004, Pages 1534-1541

  Chen, Benny J ^a   Cui, Xiuyu ^a   Sempowski, Gregory D ^a   Liu, Congxiao ^a   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MICROBIAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0842263996     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2987     Document Type: Article

References (63)

1. Armitage JO. Bone marrow transplantation [see comments]. N Engl J Med. 1994;330:827-838.
2. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192-3204.
3. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility, barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687-1698.
4. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
5. Matesic D, Lehmann PV, Heeger PS. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation. 1998;65:906-914.
6. Bishop DK, Orosz CG. Limiting dilution analysis for alloreactive, TCGF-secretory T cells. Two related LDA methods that discriminate between unstimulated precursor T cells and in vivo-alloactivated T cells. Transplantation. 1989;47:671-677.
7. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99:3083-3088.
8. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102:473-482.
9. + T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol. 1999;163:3684-3691.
10. Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50:1-7.
11. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood. 2002;99:3041-3049.
12. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. Anti-CD3 epsilon F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J Immunol. 2001;166:5835-5839.
13. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93:3550-3557.
14. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996;87:4887-4893.
15. Rencher SD, Houston JA, Lockey TD, Hurwitz JL. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant. 1996;18:415-420.
16. Mavroudis DA, Jiang YZ, Hensel N, et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant. 1996;17:793-799.
17. Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998;101:565-570.
18. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704-1714.
19. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002;360:130-137.
20. Sprent J. T-memory and B-memory cells. Cell. 1994;76:315-322.
21. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16:201-223.
22. + memory t-cells from the spleen lack Mel-14, the lymph-node homing receptor. J Immunol. 1992;148:324-331.
23. Sugimori N, Nakao S, Yachie A, et al. Administration of G-CSF to normal individuals diminishes L-selectin(+) T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin(-) T cells. Bone Marrow Transplant. 1999;23:119-124.
24. Jung TM, Gallatin WM, Weissman IL, Dailey MO. Down-regulation of homing receptors after T cell activation. J Immunol. 1988;141:4110-4117.
25. Lee WT, Vitetta ES. The differential expression of homing and adhesion molecules on virgin and memory T-cells in the mouse. Cell Immunol. 1991;132:215-222.
26. Mobley JL, Rigby SM, Dailey MO. Regulation of adhesion molecule expression by Cd8 T-cells invivo: 2, expression of L-selectin (Cd62L) by memory cytolytic T-cells responding to minor histocompatibility antigens. J Immunol. 1994;153:5443-5452.
27. McHeyzerWilliams MG, Altman JD, Davis MM. Enumeration and characterization of memory cells in the T-H compartment. Immunol Rev. 1996;150:5-21.
28. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature. 1978;272:624-626.
29. Chen BJ, Cui X, Sempowski GD, et al. A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. Blood. 2002;99:364-371.
30. Sempowski GD, Gooding ME, Liao HX, Le PT, Haynes BF. T cell receptor excision circle assessment of thymopoiesis in aging mice. Mol Immunol. 2002;38:841-848.
31. Chen BJ, Cui X, Chao NJ. Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Blood. 2002;99:2235-2240.
32. + T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101-108.
33. Zeng D, Hoffmann P, Lan F, et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood. 2002;99:1449-1457.
34. Ashwell JD, Chen C, Schwartz RH. High-frequency and nonrandom distribution of alloreactivity in T-cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol. 1986;136:389-395.
35. Medawar PB. The behavior and fate of skin autografts and skin homografts in humans. J Anat. 1944;78:176-199.
36. Lonial S, Torre C, Stuebner M, Waller EK. Indirect antigen presentation is more effective when the responder T-cell population is naive not memory T-cells [abstract]. Blood 2002;100:58b.
37. Korngold R, Sprent J. Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med. 1991;197:12-18.
38. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation. 1995;60:355-361.
39. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225-234.
40. Ahmadzadeh M, Hussain SF, Farber DL. Heterogeneity of the memory CD4 T cell response: persisting effecters and resting memory T cells. J Immunol. 2001;166:926-935.
41. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4[+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493-3499.
42. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-406.
43. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399.
44. Hertel-Wulff B, Palathumpat V, Schwadron R, Strober S. Prevention of graft-versus-host disease by natural suppressor cells. Transplant Proc. 1987;19:536-539.
45. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194:1433-1440.
46. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983;304:30-34.
47. Warnock RA, Askari S, Butcher EC, von Andrian UH. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J Exp Med. 1998;187:205-216.
48. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients [see comments]. N Engl J Med. 1996;335:157-166.
49. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors [see comments]. N Engl J Med. 1998;339:1565-1577.
50. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815-1822.
51. Rabianherzog C, Lesage S, Gluckman E. Characterization of lymphocyte subpopulations in cord blood. Bone Marrow Transplant. 1992;9:64-67.
52. Beck R, Lampotang PRL. Comparison of cord-blood and adult-blood lymphocyte normal ranges-a possible explanation for decreased severity of graft-versus-host disease after cord-blood transplantation. Immunol Cell Blol. 1994;72:440-444.
53. Early E, Reen DJ. Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses. Clin Exp Immunol. 1999;116:527-533.
54. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72.
55. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today. 1997;18:245-251.
56. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369-380.
57. Bachar-Lustig E, Reich-Zeliger S, Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood. 2003;102:1943-1950.
58. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
59. Hengel RL, Thaker V, Pavlick MV, et al. L-selectin (CD62L) expression distinguishes small resting memory CD4(+) T cells that preferentially respond to recall antigen. J Immunol. 2003;170:28-32.
60. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu SY. Isolation eased on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 1996;56:4338-4342.
61. Kagamu H, Shu SY. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol. 1996;160:3444-3452.
62. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020.
63. Chao CC, Jensen R, Dailey MO. Mechanisms of L-selectin regulation by activated T cells. J Immunol. 1997;159:1686-1694.